Management and Outcomes of Relapse After Treatment for Thymoma and Thymic Carcinoma

被引:45
|
作者
Bott, Matthew J.
Wang, Hanghang
Travis, William
Riely, Gregory J.
Bains, Manjit
Downey, Robert
Rusch, Valerie
Huang, James [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Thorac Serv, Dept Surg, Dept Pathol, New York, NY 10065 USA
来源
ANNALS OF THORACIC SURGERY | 2011年 / 92卷 / 06期
关键词
CLINICOPATHOLOGICAL FEATURES; STAGE-III; FOLLOW-UP; RECURRENCE; CHEMOTHERAPY; REOPERATION; RESECTION; THERAPY; TUMORS;
D O I
10.1016/j.athoracsur.2011.07.078
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Although surgery is the mainstay of treatment for thymic tumors, recurrence is common despite resection. The optimal approach to the management of disease relapse after treatment for thymic tumors remains unclear. Methods. This study is a retrospective analysis of a single-institution experience assessing treatment patterns and outcomes in patients with recurrence or disease progression after surgical treatment for thymic tumors. Data included demographics, stage, treatment, pathologic findings, and postoperative outcomes. Results. From 1995 to 2006, 120 patients had initial resection of a thymic tumor at our institution, of which 112 had recurrence data available. Twenty-five patients developed recurrence or progression of disease after their initial resection (10 thymic carcinoma, 15 thymoma). Median follow-up was 51.4 months. Higher Masaoka stages predominated (I: 0; II: 4; III: 8; IV: 13). Eleven patients (44%) underwent surgery for their relapse with curative intent, while 14 (56%) were managed nonsurgically. Surgery was considered when disease was intrathoracic, unilateral, and technically resectable. The 11 patients receiving surgery had a total of 16 reoperations (range 1 to 4). An R0 re-resection was obtained in half of cases (8 of 16, 50%) but the majority of operative patients (9 of 11, 82%) recurred again. The 5-year overall survival of the 25 patients with recurrent or persistent disease was 58% (median survival = 82 months). Kaplan-Meier curves demonstrate a trend (p = 0.08) toward improved overall survival in patients treated with surgery versus those treated nonoperatively (median survival = 156 months versus 50 months). Patients with thymoma demonstrated a trend (p = 0.12) toward improved survival for over thymic carcinoma (median survival = 90 months versus 35 months). Conclusions. Treatment of patients with recurrent or progressive thymic tumors is associated with long-term survival. Despite the historical enthusiasm for re-resection, the majority of patients will recur again, therefore reoperation should be considered only in selected patients.
引用
收藏
页码:1984 / 1992
页数:9
相关论文
共 50 条
  • [41] Chemotherapy for thymic carcinoma and advanced thymoma in adults
    Wei, Mao Ling
    Kang, Deying
    Gu, Lijia
    Qiu, Meng
    Liao Zhengyin
    Mu, Yanming
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (08):
  • [42] MULTIMODALITY TREATMENT FOR THYMOMA AND THYMIC CARCINOMA: RESULTS OF A SINGLE CENTER EXPERIENCE.
    Mertsoylu, Huseyin
    Kose, Fatih
    Muallaoglu, Sadik
    Sezer, Ahmet
    Besen, Ali A.
    Karadeniz, Cemile
    Ozyilkan, Ozgur
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S648 - S648
  • [43] The clinicopathological significance of thymic epithelial markers expression in thymoma and thymic carcinoma
    Li, Huiyang
    Ren, Bo
    Yu, Shili
    Gao, Hongwen
    Sun, Ping-Li
    BMC CANCER, 2023, 23 (01)
  • [44] The clinicopathological significance of thymic epithelial markers expression in thymoma and thymic carcinoma
    Huiyang Li
    Bo Ren
    Shili Yu
    Hongwen Gao
    Ping-Li Sun
    BMC Cancer, 23
  • [45] Clinical Outcomes of Up-front Surgery Versus Surgery After Induction Chemotherapy for Thymoma and Thymic Carcinoma: A Retrospective Study
    Ma, Wei-Li
    Lin, Chia-Chi
    Hsu, Feng-Ming
    Lee, Jang-Ming
    Chen, Jin-Shing
    Hsieh, Min-Shu
    Chang, Yih-Leong
    Chao, Ying-Ting
    Chang, Chin-Hao
    Yang, James Chih-Hsin
    CLINICAL LUNG CANCER, 2019, 20 (06) : E609 - E618
  • [46] A retrospective evaluation of locally advanced thymoma and thymic carcinoma: Factors influencing the prognosis after local treatment modalities.
    Arslan, Ulku Yalcintas
    Geredeli, Caglayan
    Ozdemir, Nuriye
    Ciltas, Aydin
    Sonmez, Ozlem
    Kucukoner, Mehmet
    Karaca, Halit
    Durnali, Ayse Gok
    Boruban, Melih Cem
    Zengin, Nurullah
    Buyukberber, Suleyman
    Suner, Ali
    Seker, Mesut
    Alkis, Necati
    Oksuzoglu, Omur Berna
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [47] State of the art: diagnostic tools and innovative therapies for treatment of advanced thymoma and thymic carcinoma
    Ried, Michael
    Marx, Alexander
    Gotz, Andrea
    Hamer, Okka
    Schalke, Berthold
    Hofmann, Hans-Stefan
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2016, 49 (06) : 1545 - 1552
  • [48] Thymoma/thymic carcinoma - A distinctive, unusual morphologic entity
    Moran, CA
    EPITHELIAL TUMORS OF THE THYMUS: PATHOLOGY, BIOLOGY, TREATMENT, 1997, : 17 - 21
  • [49] Single institution experience of thymoma and thymic carcinoma patients
    Simsek, M.
    Bilici, M.
    Tekin, S.
    LEUKEMIA RESEARCH, 2019, 85 : S25 - S25
  • [50] Thymoma and Thymic Carcinoma: An Update of the WHO Classification 2004
    Philipp Ströbel
    Alexander Marx
    Andreas Zettl
    Hans Konrad Müller-Hermelink
    Surgery Today, 2005, 35 : 805 - 811